Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novo Nordisk Will Add Jobs In U.S.
by Lisa M. Jarvis
May 7, 2012
| A version of this story appeared in
Volume 90, Issue 19
Danish drug firm Novo Nordisk plans to increase its U.S. workforce, now 4,100, by 15% in 2012. Sales positions will represent much of the growth in headcount, but the company says it is also recruiting scientists for its new type 1 diabetes R&D site in Seattle and workers for its manufacturing facility in Clayton, N.C. In separate news, Novo Nordisk has licensed heparosan-based drug delivery technology from Oklahoma City-based Caisson Biotech. The deal could be worth more than $100 million in milestone payments, Caisson says, if drugs using its technology reach the market.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter